Every Investor Needs to See This Marijuana Stock Price Prediction

Now that cannabis is fully legal for adults in Canada, this trend is accelerating across North America.

And we have one marijuana stock price prediction that you won't want to miss.

The legal marijuana market is set to soar in the short and long term. It produced $10 billion in sales last year, and this figure is projected to hit $24.5 billion by 2021.

marijuana leaf

This is an increase of 145% over just four years. If you are tuned in to the right pot stocks to watch, this soaring market could produce returns that will be life-altering.

Understandably, some investors are still reluctant to buy cannabis stocks.

Even though pot is legal in Canada and many other developed nations, this isn't the case in the United States, where it remains illegal under federal law.

It's difficult to tell where the current administration stands on marijuana. On the one hand, U.S. President Donald Trump supported a bill last year that prevents the DEA and DOJ from pursuing legal action against law-abiding marijuana companies in U.S. states.

However, former Attorney General Jeff Sessions ended an Obama-era rule this year, effectively allowing the opposite approach. In other words, there is no longer protection for marijuana businesses that are law-abiding.

ELECTION UPDATE: Michigan just legalized adult-use marijuana. Three stocks to watch now.

This makes it confusing for anyone who wants to invest in pot stocks.

That is not to mention the fact that many of the pot stocks you'll find today are penny stocks, which come with their own set of risks. Not only are a large percentage of penny stocks speculative and risky, but some are just downright scams.

The good news is that we've uncovered one of the top marijuana stocks to watch this year that also speaks to the investors who are still somewhat risk-averse.

This company trades on a major exchange and has been in business for three decades, so it is well established.

This is also a biopharmaceutical company that has been given positive attention by the U.S. federal government this year, which was previously unheard of for cannabis companies.

Many elements have come together for this company, whose cannabis stock price could produce double-digit returns in a short period for early investors...

This Marijuana Stock Price Prediction Calls for Double-Digit Returns

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

GW Pharmaceutical Plc. (NASDAQ: GWPH) is a British pharmaceutical company that has been in business since 1998.

It deals primarily with developing and marketing cannabis-derived solutions for rare medical conditions, mostly focusing on helping people who are suffering from seizures.

GW is notable because it has accomplished something that no other company has yet. Its main drug called Epidiolex was approved by the FDA this year.

This was the first time that the FDA has approved a marijuana-derived medication for the treatment of any condition in the United States. It is a significant achievement.

Epidiolex was developed by GW researchers using CBD that has been modified chemically. CBD, short for cannabidiol, is a compound that comes from cannabis, but it does not include THC, which is the part of the plant that produces a euphoric feeling.

GW's revolutionary drug is targeted for the treatment of two seizure-causing conditions. It will, however, be studied for application with other conditions in the future.

In June of this year, the FDA approved Epidiolex for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome, which are two types of early-onset epilepsy conditions.

Just a few months later, the FDA announced its classification for Epidiolex, which was even more good news. The drug is going to be classified as a Schedule 5 drug under the Controlled Substance Act.

This level of classification is a clear signal from the FDA that it doesn't view this cannabis-derived medication as being either dangerous or addictive.

Epidiolex began shipping nationwide to pharmacies in October, and it is now available by prescription.

These were all major announcements, and GWPH stock responded in kind to each. There were share price jumps in both June and September when FDA news came out. The stock hit an all-time high of $179.65 per share in September, but there is another buying opportunity for investors to get into this stock at a lower price.

Money Morning Defense and Tech Specialist Michael A. Robinson says that GW's revenue could soar by $1.7 billion by 2026 just due to the sale of Epidiolex.

This company has a stellar market cap of $4.78 billion, which is impressive for any pot stock. It has also announced plans to develop more marijuana-based solutions in the coming years.

The stock has been given a high price target of $227. The current pot stock price of GWPH is $125.30, which means that this one could jump another 81.16% in just one year.

President Trump Agrees with Boehner - "I Think He's Right"

Former Speaker John Boehner is well connected.

He's been inside the White House. He even golfs with the president.

And now, he's voicing his full support for marijuana legalization - and revealing the three key events that will transform the industry forever.

Click here to see his full presentation.

Follow Money Morning on FacebookTwitter, and LinkedIn.